ArticleJournal of medicinal chemistry2010
Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.
Article in Journal of medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 citations in OpenAlex.
- Mini-review and situation report on the role and usefulness of nuclear medicine imaging for malaria.European journal of nuclear medicine and molecular imaging · 2026Review
- Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs.Nature communications · 2024Observational
- Dynamic PET Reveals Compartmentalized Brain and Lung Tissue Antibiotic Exposures.Research square · 2024Article
- Recent Advancements in Radiopharmaceuticals for Infection Imaging.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis.Current HIV/AIDS reports · 2023Review
- The Promise of Molecular Imaging: Focus on Central Nervous System Infections.The Journal of infectious diseases · 2023Review
- Article
- Antibiotic-Derived Radiotracers for Positron Emission Tomography: Nuclear or "Unclear" Infection Imaging?Angewandte Chemie (International ed. in English) · 2022Review
- Highlights of the Latest Developments in Radiopharmaceuticals for Infection Imaging and Future Perspectives.Frontiers in medicine · 2022Review
- Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers.Frontiers in medicine · 2021Review
- The potential of microdialysis to estimate rifampicin concentrations in the lung of guinea pigs.PloS one · 2021Article
- Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.Nature medicine · 2020Article
- Radiotracer Development for Bacterial Imaging.Journal of medicinal chemistry · 2020Review
- Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection byFrontiers in pharmacology · 2020Article
- Molecular Imaging of Diabetic Foot Infections: New Tools for Old Questions.International journal of molecular sciences · 2019Review
- NoninvasiveScience translational medicine · 2018Article
- Recent progress in [Journal of labelled compounds & radiopharmaceuticals · 2018Article
- Quantitative PET of liver functions.American journal of nuclear medicine and molecular imaging · 2018Review
- Subcellular Partitioning and Intramacrophage Selectivity of Antimicrobial Compounds against Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2017Article
- Isolated splenic tuberculosis detected only on FDG-PET.BJR case reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The front-line tuberculosis (TB) chemotherapeutics isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) have been labeled with carbon-11 and the biodistribution of each labeled drug has been determined in baboons using positron emission tomography (PET). Each radiosynthesis and formulation has been accomplished in 1 h, using [(11)C]CH(3)I to label RIF and [(11)C]HCN to label INH and PZA. Following iv administration, INH, PZA, RIF, and/or their radiolabeled metabolites clear rapidly from many tissues; however, INH, PZA, and/or their radiolabeled metabolites accumulate in the bladder while RIF and/or its radiolabeled metabolites accumulates in the liver and gall bladder, consistent with the known routes of excretion of the drugs. In addition, the biodistribution data demonstrate that the ability of the three drugs and their radiolabeled metabolites to cross the blood-brain barrier decreases in the order PZA > INH > RIF, although in all cases the estimated drug concentrations are greater than the minimum inhibitory concentration (MIC) values for inhibiting bacterial growth of Mycobacterium tuberculosis (MTB). The pharmacokinetic (PK) and drug distribution data have important implications for treatment of disseminated TB in the brain and pave the way for imaging the distribution of the pathogen in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.